COVID-19 precipitated sarcopenia in a patient with COPD and initially preserved functional status

Leila Laouar; Nadia Debbih; Nadia Hammadi; Sonia Nouioua

doi:10.12746/swjm.v14i59.1651

Leila Laouar Youcef El Khatib University of Health Sciences, Algiers
Nadiah Dammene Debbih Laboratory of Neurosciences, Youcef El Khatib University of Health Sciences, Algeria
Nadia Hammadi Laboratory of Neurosciences, Youcef El Khatib University of Health Sciences, Algeria
Sonia Nouioua Laboratory of Neurosciences, Youcef El Khatib University of Health Sciences, Algeria

DOI: https://doi.org/10.12746/swjm.v14i59.1651

Abstract

Case Presentation: We report a case of a 67-year-old male with COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade B, who developed significant sarcopenia following a mild COVID-19 infection. Prior to infection, the patient had preserved functional capacity, with a 6-minute walk distance (6MWD) of 420 meters. During the acute phase, he experienced mild respiratory symptoms managed entirely on an outpatient basis. Three weeks post-infection, he exhibited marked proximal muscle weakness, reduced handgrip strength (21 kg), slow gait speed (0.9 m/s), and decreased 6MWD (290 m). Laboratory evaluation revealed elevated creatine phosphokinase (CPK 420 U/L) and lactate dehydrogenase (LDH 280 U/L), persistent mild lymphopenia, and low-grade systemic inflammation. Serum 25-hydroxyvitamin D, albumine and calcium levels were within normal ranges. Immunological work-up for inflammatory myopathy, including antinuclear antibodies (ANA) and anti–Jo-1 (anti–histidyl-tRNA synthetase) antibodies, was negative. A structured rehabilitation program, including respiratory therapy, postural exercises, low-intensity resistance training, and optimized protein intake (1.2-1.5 g/kg/day), was initiated.

Outcome: Over 12 months, the patient demonstrated progressive recovery of muscle strength, functional capacity, and normalization of most laboratory parameters, with residual mild proximal weakness.

Conclusion: This case underscores that COVID-19 can precipitate or unmask sarcopenia even after mild respiratory illness in COPD patients with previously preserved functional status. Systematic muscle assessment and early rehabilitation, including nutritional optimization, are essential to preserve functional independence in this vulnerable population.

Downloads

Download data is not yet available.

References

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2023 Report. 2023. Available at: www.goldcopd.org
2. Jones SE, Maddocks M, Kon SSC, Canavan JL, et al. Sarcopenia in COPD: Prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax. 2015;70(3):213–218. https://doi.org/10.1136/thoraxjnl-2014-206440
3. Benz E, Wijnant SRA, Trajanoska K, Arinze JT, et al. Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study. ERJ Open Res. 2022 Jan 10;8(1):00628-2021. https://doi.org/10.1183/23120541.00628-2021.
4. Ma K, Huang F, Qiao R, Miao L, et al. Pathogenesis of sarcopenia in chronic obstructive pulmonary disease. Front Physiol. 2022;13:850964. https://doi.org/10.3389/fphys.2022.850964
5. Henrot P, Dupin I, Schilfarth P, Esteves P, et al. Main pathogenic mechanisms and recent advances in COPD peripheral skeletal muscle wasting. Int J Mol Sci. 2023;24(7):6454. https://doi.org/10.3390/ijms24076454
6. Schols AMWJ, Ferreira IM, Franssen FME, Gosker HR, et al. Nutritional assessment and therapy in COPD: A European Respiratory Society statement. Eur Respir J. 2014;44(6):1504–1520. https://doi.org/10.1183/09031936.00070914
7. Schols AMWJ, Maltais F, Casaburi R, Barreiro E, et al.; ATS/ERS Ad Hoc Committee. Update on limb muscle dysfunction in COPD. Am J Respir Crit Care Med. 2014;189(9):e15–e62. https://doi.org/10.1164/rccm.201402-0373ST
8. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. https://doi.org/10.1038/s41591-021-01283-z
9. Berentschot JC, Bek LM, Drost E, van den Berg-Emons RJG, et al. Health outcomes up to 3 years and post-exertional malaise in patients after hospitalization for COVID-19: A multicentre prospective cohort study (CO-FLOW). Lancet Reg Health Eur. 2025;50:101290. https://doi.org/10.1016/j.lanepe.2025.101290
10. Attaway AA, Welch N, Dasarathy S, Amaya-Hughley K, et al. Acute skeletal muscle loss in SARS-CoV-2 infection contributes to poor clinical outcomes in COVID-19 patients. J Cachexia Sarcopenia Muscle. 2022;13(5):2436–2446. https://doi.org/10.1002/jcsm.13052
11. Silva CC, Bichara CNC, Carneiro FRO, Palácios VRdCM, et al. Muscle dysfunction in long COVID-19 syndrome: Pathogenesis and clinical approach. Rev Med Virol. 2022;32(6):e2355. https://doi.org/10.1002/rmv.2355
12. Zuñiga-Jimenez S, Rojas-Esguerra D, Muñoz-Martinez C, Mendoza-Guzman JS, et al. Musculoskeletal sequelae of post-COVID-19 syndrome: A systematic review. Diseases. 2025;13(12):391. https://doi.org/10.3390/diseases13120391
13. Ferrandi PJ, Alway SE, Mohamed JS. The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. J Appl Physiol. 2020;129(4):864–867. https://doi.org/10.1152/japplphysiol.00785.2020
14. Chauhan V, Pandey A, Rakshit A, Mahajan G, et al. Musculoskeletal and neuromuscular dysfunction due to COVID-19 infection: A review. Vacunas. 2023;24(Suppl 2):S154–S162. https://doi.org/10.1016/j.vacun.2023.09.004
15. Morley JE, Kalantar-Zadeh K, Anker SD. COVID-19: A major cause of cachexia and sarcopenia? J Cachexia Sarcopenia Muscle. 2020;11(4):863–865. https://doi.org/10.1002/jcsm.12589
16. Sekar J, Attaway A. The intersection of HIF-1α, O-GlcNAc, and skeletal muscle loss in chronic obstructive pulmonary disease. Glycobiology. 2023;33(11):911–926. https://doi.org/10.1093/glycob/cwad081
17. Orea-Tejeda A, Robles-Hernández R, González-Islas D, Jimenez-Gallardo JC, et al. Dynapenia and sarcopenia in post-COVID-19 syndrome hospitalized patients are associated with severe reduction in pulmonary function. J Clin Med. 2023;12(20):6466. https://doi.org/10.3390/jcm12206466
18. Pérez-Campos Mayoral L, Matias-Cervantes CA, Pérez-Campos E, Romero Díaz C, et al. Associations of dynapenic obesity and sarcopenic obesity with the risk of complications in COVID-19. Int J Mol Sci. 2022;23(15):8277. https://doi.org/10.3390/ijms23158277
19. Gatt ME, Zilber E, Perelman I, Landau Z, et al. Do low levels of alanine aminotransferase, a baseline marker of sarcopenia and frailty, associate with worse clinical outcomes among hospitalized COVID-19 patients? J Frailty Sarcopenia Falls. 2023;8(3):148–155. https://doi.org/10.22540/JFSF-08-148
20. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, et al. EWGSOP2. SARC-F and functional assessments. Age Ageing. 2019;48(1):16–31. https://doi.org/10.1093/ageing/afy169
21. Martin SS, Keeler AM, Wu X, Shearon C, et al. An alternative mechanism for skeletal muscle dysfunction in long-term post-viral lung disease. Am J Physiol Lung Cell Mol Physiol. 2023;325(1):L39–L52. https://doi.org/10.1152/ajplung.00338.2022
22. Haan J, Blackmon J, Cobb N, Cohen J, et al. Corticosteroids in critically ill patients: A narrative review. Pharmacotherapy. 2024;44(6):506–530. https://doi.org/10.1002/phar.2944
23. Imamura M, Uchyiama SST, Naves BL, Abicalaf CAP, et al. Ultrasonographic findings in long COVID: A cross-sectional study of 312 patients. Front Med. 2022;9:1051389. https://doi.org/10.3389/fmed.2022.1051389
24. Géfard-Gontier E, Le Quang M, Martin-Négrier ML, Violleau MH, et al. Glucocorticoid-induced myopathy: a comprehensive review. J Neurol. 2025 Oct 28;272(11):734. https://doi.org/10.1007/s00415-025-13482-6.
25. Khan MH, Fatima M, Adnan AB, Jawaid A, et al. Sarcopenia in chronic obstructive pulmonary disease: Mechanisms, diagnosis, and management strategies. Ann Med Surg. 2025;85(2):584–593. https://doi.org/10.1097/ms9.0000000000003584
26. Ikeda N, Oikawa T, Muraoka S, Tsukada M, et al. The effect of rehabilitation and one year follow-up for a COVID-19 patient on prolonged mechanical ventilation. Nihon Ronen Igakkai Zasshi. 2023;60(2):184–189. https://doi.org/10.3143/geriatrics.60.184
27. Gobbi M, Bezzoli E, Ismelli F, Trotti G, et al. Skeletal muscle mass, sarcopenia and rehabilitation outcomes in post-acute COVID-19 patients. J Clin Med. 2021;10(23):5623. https://doi.org/10.3390/jcm10235623
28. Volckaerts A, Vissers D, Burtin C, Van Meerbeeck J, et al. Randomised, controlled, open-label pragmatic trial evaluating changes in functional exercise capacity after primary care PUlmonary REhabilitation in patients with long COVID: protocol of the PuRe-COVID trial in Belgium. BMJ Open.2023;13(6):e071098.
https://doi.org/10.1136/bmjopen-2022-071098
29. Besnek Ç, Akkok B, Sahin H, Sahin M, et al. Determination of the frequency of sarcopenia in patients admitted with COPD diagnosis with the SARC-F survey. BMC Pulm Med. 2025 Jul 10;25(1):334. https://doi.org/ 10.1186/s12890-025-03794-8.